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Abstract Gliomas are a diverse group of brain tumors of
glial origin. Most are characterized by diffuse inﬁltrative
growth in the surrounding brain. In combination with their
refractive nature to chemotherapy this makes it almost
impossible to cure patients using combinations of con-
ventional therapeutic strategies. The drastically increased
knowledge about the molecular underpinnings of gliomas
during the last decade has elicited high expectations for a
more rational and effective therapy for these tumors. Most
studies on the molecular pathways involved in glioma
biology thus far had a strong focus on growth factor
receptor protein tyrosine kinase (PTK) and phosphatidyl-
inositol phosphatase signaling pathways. Except for the
tumor suppressor PTEN, much less attention has been paid
to the PTK counterparts, the protein tyrosine phosphatase
(PTP) superfamily, in gliomas. PTPs are instrumental in
the reversible phosphorylation of tyrosine residues and
have emerged as important regulators of signaling path-
ways that are linked to various developmental and disease-
related processes. Here, we provide an overview of the
current knowledge on PTP involvement in gliomagenesis.
So far, the data point to the potential implication of
receptor-type (RPTPd, DEP1, RPTPl, RPTPf) and intra-
cellular (PTP1B, TCPTP, SHP2, PTPN13) classical PTPs,
dual-speciﬁc PTPs (MKP-1, VHP, PRL-3, KAP, PTEN)
and the CDC25B and CDC25C PTPs in glioma biology.
Like PTKs, these PTPs may represent promising targets for
the development of novel diagnostic and therapeutic
strategies in the treatment of high-grade gliomas.
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Introduction
Like in many other cell types, accumulation of genetic
damage in glial (precursor) cells may ultimately lead
to transformation into tumor cells. The World Health
Organization (WHO) classiﬁes the resulting gliomas in
many different histological subtypes and in four different
malignancy grades [88]. Astrocytomas, oligodendroglio-
mas and mixed oligoastrocytomas are the most common
glioma types. Most of these tumors are characterized by
diffuse inﬁltrative growth in the surrounding brain paren-
chyma which precludes curative treatment by surgery or
radiotherapy alone, and together with their relative resis-
tance towards conventional chemotherapy this places these
tumors among the most intractable human malignancies
[24]. For the most frequent of these gliomas, i.e. glio-
blastoma multiforme (GBM), only 10% of the glioblastoma
patients survive 5 years post-diagnosis when receiving
combined chemo- and radio therapy as opposed to 2% for
radiation treatment alone [74, 137]. Ependymomas are
quite rare and are traditionally thought to originate from
the ependymal cells lining the ventricular walls in the brain
and the central canal in the spinal cord.
A more detailed insight in the molecular etiology of
these gliomas may open up new ways to combat these
tumors. Multiple studies towards that end, including cyto-
genetic analyses, but also genome-wide microarray
expression screens, have been performed and important
players have been identiﬁed. They mainly converge on
aberrant growth factor signaling and deregulation of cell
cycle control, processes that exploit the phosphorylation of
proteins on tyrosine residues [17, 43, 106]. This reliance on
protein tyrosine kinase (PTK) activity urges for a closer
look on the role that is played by protein tyrosine phos-
phatases (PTPs), their enzymatic counterparts (Fig. 1), in
glioma biology. The PTP enzyme family has emerged as an
important regulator of developmental and disease-related
signaling pathways [143], and multiple members are
directly linked to malformation syndromes and tumori-
genesis [54, 107]. So far, a systematic review on the role of
PTPs in gliomagenesis is lacking. Here, following a brief
discussion of the aberrant signaling pathways in glioblas-
tomas, we will introduce the general features of the PTP
family before presenting detailed information on PTP
involvement in glioma biology. The PTP enzymes
discussed may represent entry points for development of
novel diagnostics and therapies in the treatment of high-
grade gliomas.
Affected processes in gliomas
The sequential changes that transform glial (precursor)
cells into tumor cells ﬁt well with the cancer cell hallmarks
encountered in many other tumor systems [52]. First,
cancer cells have acquired the ability to be self-sufﬁcient in
providing growth signals while reducing their sensitivity to
growth-inhibitory signals. The molecules and pathways
involved in gliomas include alterations in Ras and PI3K
(phosphatidylinositol-3-kinase) signaling pathway compo-
nents, which regulate proliferation, survival and
differentiation. Especially, genes encoding the receptor
PTKs for epidermal growth factor (EGFR) and platelet-
derived growth factor (PDGFR) are frequently mutated,
Fig. 1 Reversibility of signaling pathways by virtue of protein
tyrosine phosphatase activity. The opposing actions of PTK and
protein tyrosine phosphatase (PTP) enzymes provide the cell with a
functional diad that regulates the activity of the mutual substrates
through phosphorylation of tyrosine (Y) residues in a reversible
manner. Note that phosphorylation itself may well regulate the
activity of PTKs and PTPs themselves. Therefore, PTPs do not simply
repress or undo PTK activity; they may synergize or cooperate
in situations where tyrosine phosphorylation boosts PTP activity or
dephosphorylation activates the PTK. Some PTPs have a so-called
dual speciﬁcity; in addition to their activity towards phosphotyrosine
they are also able to dephosphorylate serine (S) and/or threonine (T)
residues in protein substrates that have been phosphorylated by serine/
threonine kinases (S/T-K). A subset of these dual-speciﬁc PTPs, most
notably the tumor suppressor protein PTEN, even demonstrate the
potential to dephosphorylate phospholipid substrates like phosphati-
dylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) that is produced by
phosphatidylinositol-3-kinase (PI3K)-mediated phosphorylation of
PtdIns(4,5)P2 (phosphatidylinositol-4,5-bisphosphate)
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123and also alterations in the ﬁbroblast growth factor (FGFR)
and hepatocyte growth factor/scatter factor (cMET)
receptor PTK genes have been documented [17]. Proteins
involved in the subsequent signaling downstream of these
PTK receptors have been linked to gliomagenesis as well
(Fig. 2). Mutations in two tumor suppressor genes, NF1
and PTEN (Phosphatase and tensin homolog on chromo-
some 10), are found in a considerable portion of
glioblastomas and also genetic changes in Akt and Ras
have been documented [17]. The involvement of PTEN and
other PTP family members will be described in more detail
later on.
Secondly, glioma cells tend to evade apoptosis and
senescence. The TP53 gene, encoding a key regulator of
cell cycle progression, DNA repair, cellular senescence,
apoptosis and angiogenesis [152], is frequently inactivated
at an early stage in gliomagenesis. Alternatively, other
important players that affect p53 functioning, e.g. the p53
activator p14ARF or the negative p53 regulators MDM2
and MDM4 (Fig. 2) are deleted or ampliﬁed in gliomas,
respectively. In addition, glioma cells may exploit several
other mechanisms to evade apoptosis, including abrogated
PI3K signaling (Fig. 2), genetic alterations in death
receptor and mitochondria-dependent pathways via Bcl2-
like-12 [135, 136], and inactivation of the retinoblastoma
(Rb) tumor suppressor pathway (Fig. 2). The Rb pathway
controls the cell cycle entry step into the DNA replication
phase [46]. Many of the involved proteins are genetically
altered in GBMs: the CDK4 and CDK6 genes are often
ampliﬁed, while Rb is deleted or mutated in *11% of the
glioblastomas [17]. Normally, continued proliferation of
somatic cells leads to senescence due to successive short-
ening of chromosome ends, the telomeres [14]. High-grade
gliomas bypass telomere shortening, hence senescence,
either by restoring embryonal telomerase activity [128]o r
by exploiting a telomere maintenance mechanism that
involves recombination-based interchromosomal exchan-
ges of DNA segments [55].
Thirdly, gliomas elicit angiogenesis and invade sur-
rounding tissues. GBMs are among the most highly
vascularized solid tumor types [66] and this may be due to
mutations in the key glioma genes PTEN and EGFR that
feed into the HIF1a pathway [68]. HIF1a is a transcription
factor that normally accumulates under hypoxic conditions
and then activates factors involved in angiogenesis and cell
survival [127], including the vascular endothelial growth
factor (VEGF) and VEGF receptor families (Fig. 2). In
glioma specimens, this activation may be independent of
hypoxia [110] and often gives rise to abnormal microvas-
culature that results in thrombosis and microhemorrhages,
Fig. 2 Interplay of PTP signaling and the major pathways affected
in glioblastomas. The Ras/PI3K, p53 and Rb signaling pathways,
which are often altered in glioblastomas, are shown in a cellular
context. For simplicity, only major factors that are described in the
text are depicted. Proteins shown in vermillion are frequently
hyperactive in gliomas (due to ampliﬁcation/mutation) while
proteins in blue are frequently hypoactive or even inactive (as a
result of mutation/deletion). The (mostly green) asterisks represent
the receptor-type and non-transmembrane PTPs (protein names are
used) that are discussed in the text and in Table 1, and the ways
how they feed into the Ras/PI3K, p53 and Rb pathways and affect
cellular processes (boxed text) is depicted. Arrows indicate interac-
tions that result in stimulation, lines ending with a perpendicular
bar indicate inhibitory interactions. Dashed lines reﬂect indirect
interaction pathways. PIP2 phosphatidylinositol-4,5-bisphosphate,
PIP3 phosphatidylinositol-3,4,5-triphosphate
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123paradoxically causing hypoxia and eventually tumor
necrosis. ‘Dispersion’ of glioma cells in the surrounding
brain tissue is distinct from the invasion and metastasis as
displayed by other tumors [24], but still many parallels
exist. Like in epithelial tumors, several integrins, including
avb3, are upregulated in gliomas [82]. In addition, the
expression of the N-cadherin cell adhesion molecule and its
associated protein b-catenin is increased at the borders of
GBMs [149]. In addition, the levels of matrix metallopro-
teases (MMPs) and non-MMP proteases, instrumental in
degrading surrounding extracellular matrix, have been
reported to be elevated in gliomas [146]. Low-grade glio-
mas usually have normal protease levels [153, 157], but
still display an invasive phenotype, suggesting that
increased protease activity is not required for glioma
dispersal.
Protein tyrosine phosphatases
Reversible tyrosine phosphorylation of proteins (Fig. 1)
plays an important role in the regulation, proliferation and
differentiation of cells and the development and function of
tissues and organisms [143]. The exploitation of this sig-
naling mechanism to drive gliomagenesis is reﬂected in the
altered activities of PTK growth factor receptors and their
downstream effectors that have been observed in tumor
specimens (as depicted in Fig. 2) and warrants a closer
look on the role of the catalytic opponents of PTKs, the
PTPs.
There are 107 genes in the human genome that belong to
the PTP superfamily of enzymes and, based on the
sequence homology of their catalytic domains and these
have been categorized into four different classes [6]. Class
I comprises 38 so-called ‘classical’ PTPs, i.e. enzymes that
exclusively dephosphorylate phosphotyrosine residues, as
well as 61 dual-speciﬁcity PTPs (DSPs). As suggested by
the name, DSPs can also dephosphorylate phosphoserine
and phosphothreonine residues, and some even display
a preference for phosphatidylinositol phosphates and
mRNAs as substrates [115]. The 38 classical PTPs can be
further subdivided into transmembrane, receptor-like
(RPTPs) and non-receptor-type PTPs [54]. In the human
genome, there is only a single Class II gene (ACP1). It
encodes the low-molecular weight PTP, termed LMPTP,
that is speciﬁc for phosphotyrosine residues [117]. Class III
comprises three CDC25 homologs that dephosphorylate
tyrosine and threonine residues within cyclin-dependent
kinases (CDKs), which participate in cell cycle regulation
[120]. Class IV consists of the eyes absent (Eya) proteins,
which recognize phosphorylated tyrosine, or dual serine
and tyrosine residues and function as transcriptional regu-
lators [65]. Recently, Eya was shown to dephosphorylate
tyrosine phosphorylated histone H2AX, thereby regulating
the recruitment of pro-apoptotic and/or DNA repair factors
to sites of DNA damage [27, 78].
Each PTP class is believed to originate from a distinct
ancestral gene and as such the clear similarity in the
dephosphorylation mechanism they exploit provides an
impressive example of convergent evolution. A common
feature of the PTP classes I, II and III is the PTP signature
motif (H/V)C(X)R(S/T) in their catalytic domain [138].
The cysteine residue is essential for catalytic activity; the
target phosphate group is transferred from the substrate
onto this catalytic site cysteine, producing a thiol inter-
mediate, and is subsequently released via hydrolysis [8].
The Eya Class IV phosphatases use a slightly different
mechanism, in which aspartate instead of cysteine plays a
crucial role in a metal-dependent reaction. Outside the
catalytic domain, PTPs are very diverse in their structure.
Multiple additional protein domains, such as protein–pro-
tein interaction or phospholipid-binding motifs, help to
diversify their functions (Fig. 3).
PTPs in tumorigenesis
Because multiple PTKs have been identiﬁed as proto-
oncogenes, it was initially believed that many PTPs might
be rapidly uncovered as tumor suppressors. However, it
turned out that there is a considerable redundancy with
regard to PTP functioning. Furthermore, PTPs may not
simply oppose PTK actions but, as some kinases are
(auto)inhibited by phosphorylation, could also act in syn-
ergy. Thus, next to some tumor suppressors, the PTP
superfamily also harbors proto-oncogenes [107]. Before
turning to the involvement of PTPs in gliomagenesis, the
evidence implicating PTPs in other tumors will be
summarized.
In fact, PTEN represents the only PTP that can unam-
biguously be termed a tumor suppressor, i.e. the gene is
frequently deleted or mutated in tumor specimens [70].
Ironically, it is not PTEN’s protein dephosphorylation
capacity, but its ability to dephosphorylate D3-phosphoi-
nositosides—and thereby dampen PI3K-Akt signaling—
that is crucial for maintaining tissue homeostasis [90, 102].
Several other PTP genes are deleted or mutated in cancer
tissues as well, but the frequency is usually quite low and
causal relationships often have not been assessed. A screen
encompassing 87 out of the 107 human PTP genes revealed
mutations for six of them, all encoding classical PTPs
(PTPRF, PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14)
in 26% of the colon cancer samples analyzed [154].
Alterations in these genes were also identiﬁed in lung,
breast and gastric cancer samples, but at an even lower
frequency. For PTPRT, the most frequently mutated PTP
160 Acta Neuropathol (2010) 119:157–175
123out of these six, growth suppressive activity was indeed
demonstrated in cell transfection experiments, underscor-
ing the relevance of this PTP in cell growth regulation
[154]. The majority of cancer-related PTPRT mutations
affects the extracellular domain that mediates homophilic
cell–cell interactions, suggesting that mutation of this
phosphatase supports tumor migration [159]. The signaling
pathways that are regulated by PTPRT remain to be dis-
closed, but recently the signal transducer and activator of
transcription 3 (STAT3), that plays an important role in a
variety of hematopoietic malignancies and solid tumors
[158], was identiﬁed as a PTPRT substrate [163]. Extensive
sequence analysis screens have also revealed genetic
alterations in some other classical PTP genes (PTPRJ,
PTPN6, PTPRO, PTPN1), implicating these as potential
tumor suppressors [107].
As stated above, some PTPs might even function as
oncogenes. Currently, the only PTP gene for which this has
been demonstrated is PTPN11 that encodes the classical
PTP SHP2 [20]. SHP2 (Fig. 3) is normally in an inactive
conformation due to an intramolecular interaction of its N-
terminal SH2 domains with the catalytic PTP domain at its
C-terminus. SHP2 mutations as observed in hematological
malignancies and some solid tumors disrupt this interac-
tion, thereby constitutively activating the phosphatase [85,
141]. Then, this synergizes with growth factor and cytokine
stimuli that run via the Ras-ERK, AKT and STAT5 sig-
naling routes [99], all pathways that have important roles in
growth, proliferation and survival. How exactly SHP2 is
stimulating these ligand-gated signaling pathways, i.e.
which speciﬁc targets it dephosphorylates, remains con-
troversial, but the dephosphorylation and consequent
activation of Src family kinases is a likely scenario [20].
Indications that other PTPs also have oncogenic potential
are more indirect. Several classical PTP genes are over-
expressed in human cancers, including PTPRA, PTPRH,
PTPRF, PTPN1, PTPN6 and PTPN7, but these may reﬂect
homeostatic adaptation to enhanced kinase activities [107].
Fig. 3 Domain structure of the PTP superfamily members implicated
in glioma biology. Schematic representations of class I transmem-
brane receptor type and intracellular ‘classical’ PTPs are given in the
upper and middle part of the ﬁgure, respectively. The lower part
shows the class I dual-speciﬁc phosphatases and the class III CDC25
family members. Thus far, class II and class IV type PTPs have not
been implicated in gliomagenesis. Alternative splicing of genes
PTPRZ and PTPN2 leads to expression of three variants of RPTPf
[87] and two of TCPTP [60], respectively. PTP protein names are
used here (Table 1), and isoform names are in italics. Protein domain
names and acronyms are indicated and the curly tail in PRL-3
represents its C-terminal prenylation. CA carbonic anhydrase-like
domain, FERM band 4.1/ezrin/radixin/moesin homology domain,
FNIII ﬁbronectin type III repeat, Glyc glycosylation sites encoded
within PTPRZ exon 12, Ig immunoglobulin-like repeat, KIND kinase
non-catalytic C-lobe domain, MA membrane-associated domain,
MAM meprin/A5-protein/PTPl homology domain, PDZ PSD-95/
discs-large/ZO-1 homology domain, PTP catalytic protein tyrosine
phosphatase domain, SH2 Src homology 2 domain, TM transmem-
brane domain. Drawings are to scale (bar corresponds to 500 amino
acid residues)
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123Further studies are needed to address the contribution of
these PTPs in tumor development in a more direct way.
Linking PTPs to glioma biology
It has also been investigated whether PTPs are relevant
players in glioma development. Indeed, 15 out of the 107
PTP genes are implicated in some way. In Table 1, the
observational data on these PTPs and gliomagenesis are
summarized and on the following pages, their involvement
is discussed in more detail (in the subheadings ﬁrst the
ofﬁcial gene name and between brackets the common
protein name will be given). Undoubtedly, the number of
studies and the fraction of PTPs that are involved in gli-
omagenesis will increase in the coming years. However, it
is to be expected that genome-wide microarray datasets
will only make a limited contribution to this, due to the
very low expression levels of most PTP genes; hence, more
PTP-focused approaches are required.
PTPRD (RPTPd)
RPTPd, a cell adhesion molecule-like RPTP with ﬁbro-
nectin type III (FNIII) and immunoglobulin-like (Ig)
repeats in its extracellular domain (Fig. 3), is mainly
expressed in brain. Mouse model studies revealed its
importance in hippocampal learning and memory [145].
PTPRD is located on chromosome 9p23–24.1, a genomic
region that is often lost during the progression from low- to
high-grade gliomas of the astrocytoma and oligodendro-
glioma types [61]. Two recent studies on GBMs report
focal homozygous deletions at the PTPRD locus that do not
impart surrounding genes [130, 150]. Also, missense or
nonsense mutations in the PTPRD gene or hypermethyla-
tion of the PTPRD promoter were frequently encountered
[130, 150], and the loss of RPTPd expression predicts for
poor prognosis in these patients [150]. PTPRD mutations
and deletions are also common among other tumors [29,
31, 125, 133]. In melanomas and lung carcinomas, these
mutations are distributed all over the PTPRD gene. The
alterations that were detected in GBM samples more locate
to the RPTPd extracellular part than to the intracellular
PTP domains [130, 150]. The re-introduction of functional
RPTPd in GBM cell lines harboring PTPRD mutations or
deletions leads to reduced proliferation and an increase in
apoptotic cells [130]. Transfection experiments pointed to
STAT3 as an RPTPd substrate [150] and, interestingly,
aberrant activation of STAT3 is commonly observed in
GBM specimens [116]. Thus, RPTPd has a tumor sup-
pressor function in a variety of tissues. In glial cells, this
activity may require its putative cell adhesion potential as
well as phosphatase activity (Fig. 2).
PTPRJ (DEP-1)
PTPRJ encodes the transmembrane protein DEP-1 that
consists of a single intracellular PTP domain and eight
FNIII repeats in its long extracellular part (Fig. 3). DEP-1
is able to counteract the signaling of several RTKs,
including PDGFR, VEGFR2 and MET [77, 108, 139],
pointing to a role as tumor suppressor (Fig. 2). Indeed, it
was shown to negatively regulate cellular growth [69]. In
glioma cells, DEP-1 is instrumental in the growth-inhibi-
tory effect of somatostatin by dephosphorylating and
inactivating the MAP kinase ERK [93, 94]. DEP-1
expression is detectable in only a subset of gliomas and
expression levels correlate well with somatostatin’s anti-
proliferative effects [93, 94]. Not much is known about
possible alterations in the PTPRJ gene in glioma specimen.
Thus far, an ampliﬁcation of the chromosome 11p11.2
region, which contains the PTPRJ gene, has been detected
in an angiocentric glioma [114]. Angiocentric gliomas are
grade I tumors that contain features of both astrocytic and
ependymal differentiation [88]. PTPRJ ampliﬁcation would
not correspond with a suggested tumor suppressor function
for DEP-1 but, since only one case has been described,
clearly more angiocentric glioma samples need to be
studied before conclusions can be drawn.
PTPRM (RPTPl)
The cell surface receptor RPTPl is a homophilic cell–cell
adhesion molecule expressed in neuronal, glial and endo-
thelial cells (Fig. 3). RPTPl not only forms an adhesive
contact itself, but it also regulates cell adhesion by
dephosphorylating components of the cadherin–catenin
complexes. In addition, the rigidity of the extracellular part
of the molecule is thought to dictate the location of this
phosphatase in cell–cell spacings [7] in line with a role
for this PTP in cell contact signaling processes. When
compared with normal brain tissue and low-grade astro-
cytomas, full-length RPTPl protein expression is lost
speciﬁcally in GBM [15]. To investigate whether this
inﬂuenced cell adhesive and migratory characteristics,
RPTPl knockdown experiments were performed in a GBM
cell line. Reduced RPTPl levels resulted in morphological
changes and an increased migration in vitro, and in a
mouse xenograft model of intracranially injected GBM
cells RPTPl knockdown caused morphological heteroge-
neity in the grafts [15]. These data put forward RPTPl as a
‘migration suppressor’ with regard to the diffuse inﬁltrative
growth pattern observed in human gliomas (Fig. 2). A
more recent study revealed that the RPTPl downregulation
in GBM results from proteolytic breakdown which releases
an active PTP fragment in the cytosol [16]. Interestingly,
both overexpression of RPTPl and shRNA-mediated
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123reduction of the RPTPl intracellular fragments suppressed
migration and growth factor-independent survival of glio-
blastoma cells. Apparently, decisions in glioma cells on
proliferation versus cell death or adhesion versus migration
are dependent on the relative levels of full-length RPTPl
and RPTPl intracellular domain. Importantly, application
of a peptide inhibitor of RPTPl phosphatase activity also
resulted in a reduction of glioma cell migration [16],
warranting further studies towards RPTPl targeted
therapeutics.
PTPRZ (RPTPf)
The classical PTP gene that currently has the strongest
links with gliomagenesis is PTPRZ, which encodes RPTPf
[80]. Originally, the cDNA was cloned by two different
groups, who termed the encoded protein PTPf [79] and
RPTPb [83], respectively. This is causing quite some
confusion in the literature, also because the name RPTPb is
nowadays linked to the protein encoded by the gene
PTPRB [6]. As a result of alternative splicing, PTPRZ
encodes three variants that may have different roles in glial
differentiation (Fig. 3). Long and short transmembrane
RPTPf isoforms are present in glial precursor cells. In
more mature glia, a secreted version called phosphacan is
expressed, which lacks the PTP part and consists of the
RPTPf extracellular domain [18]. Pleiotrophin (PTN) has
been identiﬁed as a ligand for RPTPf [89]. It induces cell
migration, at least in part by binding and clustering RPTPf,
and thereby inhibiting its phosphatase activity [42, 96].
Fibroblasts that overexpress PTN acquire a transformed
phenotype suggesting that PTN may function as an onco-
gene [21]. In line with this, several carcinoma patients
showed increased PTN levels in both serum and tumor
material [131]. PTN is overexpressed in GBM tissues as
well [147] and may exert an oncogenic effect through the
inactivation of RPTPf.
The role of RPTPf in glioma development is as yet
unclear. PTPRZ overexpression in tumor material is cor-
related with increased malignancy [101, 147]. Some other
cancer variants also display increased PTPRZ expression
[38]. Although in normal adult brain it is mainly phosph-
acan that is expressed, all three PTPRZ isoforms can be
found in gliomas. Knockdown of RPTPf leads to a
decrease in GBM growth, both in vitro and in vivo [148],
but the mechanism that may explain this growth advantage
resulting from RPTPf overexpression remains unclear.
After all, excess of RPTPf would be expected to function
as a potential PTN scavenger, thus neutralizing PTN’s
oncogenic abilities. The tumor-promoting effect of RPTPf
may be explained by mechanisms independent of PTN, for
instance through the effects of other RPTPf ligands that
include growth factors, extracellular matrix proteins and
neuronal cell adhesion molecules [111]. Neuronal adhesion
molecule binding by RPTPf is thought to inﬂuence neu-
ron–glial cell interactions and cell migration, e.g. by
promoting transcriptional activity of NFjB[ 87] which is
implicated in the integration of signals involved in adhe-
sion and migration. In addition, a recent study revealed that
the endothelial integrin avb3 not only interacts with both
PTN and RPTPf, but in doing so mediates the stimulatory
effect of PTN on cell migration and angiogenesis [97].
Thus, the overexpression of RPTPf may provide an
advantage for GBM cells by promoting their migration,
even on endothelial cell tracks [142]. Alternatively,
because proteolytic cleavage involving MMPs and prese-
nilin/c-secretase was shown to produce an RPTPf
intracellular fragment that displays nuclear localization
[23], even more direct effects at the transcriptional level
should be considered. Finally, altered RPTPf levels have a
bearing on neurotrophic signaling pathways in view of the
recent identiﬁcation of tropomyosin-related kinase A,
TrkA, a nerve growth factor receptor that is highly
expressed in the developing nervous system, as an in vivo
RPTPf substrate [129]. Also because high RPTPf levels
were reported in oligodendrogliomas as opposed to
(oligo)astrocytomas within the grade II gliomas [49], a
further evaluation of RPTPf’s contribution to gliomagen-
esis is warranted.
PTPN1 (PTP1B)
The cytoplasmic, ER membrane-associated phosphatase
PTP1B (Fig. 3) is overexpressed in several tumors,
including mammary and ovary carcinomas, but it is unclear
as yet whether it should be viewed as a potential oncogene
or a tumor suppressor [107]. PTP1B can act as a positive
regulator of Ras signaling, partly by modulating
p120RasGAP levels [33] and it is also able to activate the
oncogene protein Src [11]. Importantly, the elimination of
PTP1B activity in MMTV-neu induced mammary tumors
in mice signiﬁcantly delayed tumor growth and prevented
lung metastasis, whereas PTP1B overexpression in mam-
mary tissue led to spontaneous breast cancer development
[9, 67]. In contrast, PTP1B effectively inhibits signaling of
several oncogenic tyrosine kinases [50], while inactivation
of the gene in TP53 knockout mice accelerates the spon-
taneous development of lymphomas [32].
In gliomas, no ampliﬁcation of the PTPN1 gene has
been found [118]. However, PTP1B may well be of rele-
vance for glioma therapy. The treatment of tumor cells
derived from a primary GBM patient with troglitazone led
to PTP1B activation and subsequent dephosphorylation of
STAT3, a negative regulator of Fas-mediated apoptosis
that controls anti-apoptotic FLIP and Bcl-2 protein levels
[4]. Thus, PTP1B activity may facilitate at least one way of
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recently it was found that STAT3 not only functions in
transcription regulation in the nucleus in response to
cytokine and tyrosine kinase oncoprotein signaling, but that
in addition it is required in mitochondria for the alterations
in energy metabolism that support Ras-dependent malig-
nant transformation of cells [47, 155]. Reasoning along
these lines, PTP1B activity could potentially counteract
STAT3s moonlighting activity in mitochondria and in this
way hamper the glioma cell’s adaptation to a more gly-
colytic, hypoxic growth state (Fig. 2). Taken together,
depending on the cell type, PTP1B has distinct functions,
but current data are more in favor of a tumor suppressive
rather than an oncogenic role in GBM. Investigations on
PTP1B as a drug target [162] principally relate to diabetes
[34], and several inhibitors have been tested clinically.
PTPN2 (TC-PTP)
TC-PTP is an intracellular PTP that is ubiquitously
expressed and that is highly similar in amino acid sequence
to PTP1B (Fig. 3). As a consequence, these PTPs have
different as well as overlapping substrates and thus may
fulﬁll complementary as well as redundant roles in health
and disease [34]. Alternative splicing of PTPN2 transcripts
leads to two protein isoforms; a 48 kDa variant localized at
the endoplasmic reticulum and a 45 kDa variant, TC45,
that lacks the hydrophobic C-terminus [19, 28, 100]. TC45
is usually found in the nucleus but upon proper stimuli it
can also reside in the cytoplasm. Interestingly, TC45 cau-
ses a reduced proliferation of U87MG glioblastoma cells
that are engineered to express the glioma-associated trun-
cated protein EGFRvIII when compared with normal
U87MG cells [73]. This might well be caused by inhibition
of ERK and PI3K signaling due to direct dephosphoryla-
tion of EGFRvIII (Fig. 2). Injection of TC45- and
EGFRvIII-overexpressing U87MG cells in the brains of
nude mice revealed that also in vivo TC45 expression leads
to reduced growth of EGFRvIII-expressing tumors [73].
Although no altered TC45 activity levels in gliomas have
been reported to date, the potential of TC-PTP to coun-
teract EGFRvIII activity in vivo may be of therapeutic
value.
PTPN11 (SHP-2)
So far, PTPN11 is the only PTP that was proven to function
as an oncogene in certain tumors [20, 107]. It contains two
Src homology type 2 (SH2) domains that function as
phosphotyrosine-binding domains (Fig. 3). Activating
germline PTPN11 mutations are found in patients with
Noonan syndrome, a developmental disorder characterized
by an increased risk of malignancies. Somatic mutations
that activate PTPN11 occur in several types of hematologic
malignancies, most notably juvenile myelomonocytic leu-
kemia. The role of SHP-2 in RAS/ERK signaling (Fig. 2)
is thus well established in tumor development. Germline
mutations that impair phosphatase activity and turn
PTPN11 into a dominant-negative mutant are causative of
LEOPARD (lentigines, electrocardiogram abnormalities,
ocular hypertelorism, pulmonic stenosis, abnormalities of
genitalia, retardation of growth, and deafness) syndrome,
which also predisposes to the development of cancers such
as myelodysplastic syndrome, acute myelogenous leuke-
mia or neuroblastoma. It remains an intriguing conundrum
why Noonan and Leopard syndrome mutations result in
partly similar pathologies despite their quite opposite
effects on SHP2 catalytic function [45].
The expression of SHP-2 in the U87MG GBM cell line
resulted in increased AKT phosphorylation upon EGF
stimulation [156], underscoring that SHP-2 also facilitates
growth factor signaling in glial cells. PTPN11 mutations in
gliomas are rather uncommon [64, 91] but other compo-
nents in the RAS/PI3K pathway, like EGFR, NF1 and
RAS, are genetically altered in the majority (88%) of
GBMs [17]. Only a single PTPN11 mutation, in a grade II
oligodendroglioma patient, has been described thus far
[91]. This missense mutation in the SH2 domain of SHP-2
promotes its phosphatase activity and thus resembles the
Noonan syndrome type of activating mutations. Although
PTPN11 can display oncogenic behavior in other tumor
types, and plays an important positive role in Ras signaling
in gliomas as well, it does not represent a speciﬁc target in
these tumors.
PTPN13 (PTPN13)
The large cytosolic PTP PTPN13 (Fig. 3) appears to be
endowed with tumor suppressive as well as oncogenic
potential [2]. Support for a tumor suppressive role comes
from mutation screens in colon, breast, lung and ovarian
cancer specimens [119, 154] and our ﬁnding that high-risk
human papillomavirus (HPV) protein E6-induced degra-
dation of PTPN13 in squamous epithelial cells contributes
to oncogenic transformation [132], at least in part by
augmenting the Ras/Erk signaling pathway. In line with
this, PTPN13 inactivating mutations and enhanced Erk
activity was detected in HPV-negative head and neck
squamous cell carcinomas [56]. Contrasting with the
above, several studies have pointed to a tumor-promoting
activity of PTPN13. The PTPN13 gene is a target for the
transcription regulator fusion protein EWS-FLI1 and the
resulting overexpression of PTPN13 in Ewing’s sarcoma
cells boosts cell growth and motility [1]. Furthermore,
PTPN13 expression in a variety of tumors provides
the cancer cells with a survival mechanism, by inhibiting
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instrumental in tumor cell survival through its interactions
with p75NTR, TRPM2 and IjBa, all proteins that modu-
late cell stress signaling [2].
PTPN13’s link to FAS-induced apoptosis appears rele-
vance for glioma biology (Fig. 2). FAS is a death receptor
that, upon activation by its ligand, induces caspase cas-
cades leading to cleavage of proteins and apoptosis.
PTPN13 attenuates FAS receptor cell surface levels by
inhibiting the export of the FAS receptor from intracellular
stores to the cell membrane [62]. PTPN13 expression is
speciﬁcally upregulated in GBM tissues [39] and knock-
down of PTPN13 in GBM cell lines indeed results in
increased FAS-mediated apoptosis. In addition, PTPN13
directly interacts with and dephosphorylates FAS in a FAS
ligand-dependent manner, thereby reducing the ability of
glioma cells to undergo FAS-mediated apoptosis [39].
Hence, PTPN13 might play a role in the aforementioned
apoptosis resistance that is displayed by gliomas and that
complicates their treatment with chemo- and radiotherapy.
DUSP1 (MKP-1)
Dual-speciﬁcity MAP kinase phosphatases (MKPs) are
capable of dephosphorylating phosphotyrosine as well as
phosphothreonine residues of MAP kinases and thus
inﬂuence important cellular processes such as proliferation,
differentiation, apoptosis and survival [115]. MKP-1
(Fig. 3) is induced by growth factors and dephosphorylates
the MAP kinases JNK (Jun N-terminal Kinase), p38 and
ERK1/2. The apoptosis-inducing effect of the chemother-
apeutic drug etoposide in a glioma cell line was shown to
be PKCd-dependent, involving the ubiquitin-mediated
degradation of MKP-1 and resulting in increased ERK1/2
phosphorylation [86]. Likewise, MKP-1 levels are
decreased when glioma cells are treated with cadmium,
another apoptosis-inducing compound that also leads to
increased MAP kinase phosphorylation [72]. On the other
hand, the inhibitory effect of dexamethasone and rosiglit-
azone on glioma cell invasiveness rather depends on an
increase in MKP-1 levels in glioma cells [63, 84]. Thus,
both anti-apoptotic and anti-migratory aspects are to be
considered for MKP-1 as a potential target in glioma
therapy (Fig. 2).
DUSP26 (VHP)
The gene DUSP26 is expressed in brain and retina. It
encodes VHP (Fig. 3), a dual-speciﬁcity phosphatase with
unclear function. VHP has been implicated in MAP kinase
dephosphorylation and in upregulation of cell–cell adhe-
sion [140]. The latter is the result of VHP’s ability to
dephosphorylate Kap3, a subunit of the KIF3 motor
complex that is involved in the transport of cadherin/
catenin components from intracellular vesicles to the cell
membrane at sites of cell–cell contact. If VHP promotes
cell–cell adhesion, a process that is lost in diffusively
inﬁltrating gliomas, one may expect impaired VHP activity
in GBM material. Indeed, in eight out of nine cases, a
quantitative PCR analysis of mRNA levels showed that
DUSP26 transcript levels were decreased in GBM patient
samples when compared with normal brain tissue [140].
This may be taken as evidence that VHP is an important
regulator of cellular adhesion in glial cells (Fig. 2) and
urges for studies involving additional samples and func-
tional read-outs. In anaplastic thyroid cancer samples,
however, DUSP26 expression levels were found to be
upregulated. The DUSP26 overexpression stimulated the
growth of these cells, most likely through the dephospho-
rylation of p38 and thus inhibition of p38-mediated
apoptosis, whereas it had little effect on Erk1/2 MAP
kinases [160]. This would rather point to DUSP26 as being
an oncogene.
PTP4A3 (PRL-3)
Phosphatase of regenerating liver (PRL) enzymes is unique
in the PTP family because of their C-terminal CAAX
prenylation motif (Fig. 3). Not much is known about the
nature of their substrates [115]. In dividing cells, PRLs are
located at the mitotic spindle, but in interphase cells they
are membrane associated. It is conceivable that this cell
cycle-dependent localization conﬁnes PRL access to sub-
strates. Several studies tie PRL members to oncogenic
events such as angiogenesis, cell invasion, motility and
metastasis [122], and proposed modes of action include
stimulation of Src, Rho or PI3K signaling pathways. The
PRL-3 protein was found to display a conspicuous
expression pattern during gliomagenesis. In normal brain
tissue and grade I gliomas, no PRL-3 is detectable, whereas
grade II gliomas display low PRL-3 levels. In high-grade
glioma tissues strong PRL-3 expression is observed [75].
Interestingly, the PRL-3 levels correlate with that of sev-
eral matrix metalloproteinases that are instrumental in the
proteolytic degradation of the extracellular matrix, sug-
gesting that PRL-3 is associated with glioma invasion
(Fig. 2).
CDKN3 (KAP)
KAP was identiﬁed as a cell cycle regulating protein
because of its ability to dephosphorylate Cdk2, thereby
inhibiting G1-S phase progression [48, 53]. KAP also binds
two other cell cycle regulators, Cdk3 and cdc2, but it
remains to be determined whether these also serve as KAP
substrates. It therefore came as a surprise that astrocytomas
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well with increasing malignancy grade and decreased
patient survival [161]. A closer examination revealed that
in primary GBM tissues CDKN3 transcripts are spliced
differently, leading to the expression of a dominant-nega-
tive KAP variant. Thus, the aberrant splice variant
interferes with normal KAP functioning and, as a conse-
quence, increases the Cdk2-dependent proliferation of
GBM cells (Fig. 2). The reduction in KAP activity also has
a bearing on the migration of glioma cells, but this reﬂects
KAP phosphatase-dependent regulation of cdc2 protein
levels and hence cdc2-dependent cell motility [161].
PTEN (PTEN)
The paradigm of PTP involvement in glioma development
is PTEN. PTEN is a dual-speciﬁcity phosphatase (Fig. 3)
and is thus able to dephosphorylate phosphorylated serine,
threonine and tyrosine residues in vitro, with a preference
for extremely acidic substrates [103]. Germline mutations
in PTEN give rise to a whole series of seemingly unrelated
syndromes including Cowden disease, an autosomal dom-
inant disorder characterized by multiple hamartomas and
predisposition to breast, thyroid and endometrial carcino-
mas [36]. Intriguingly, it is PTEN’s capability to
dephosphorylate phosphaditylinositol-3,4,5-triphosphate
(PIP3)[ 90] (Figs. 1, 2) that appears most relevant in vivo
and has turned PTEN into the second-most inactivated
tumor suppressor protein in human cancers [70]. Key in
this notion was a missense mutation in a Cowden patient,
which disrupted the phosholipid phosphatase activity of
PTEN but did not affect its protein phosphatase activity
[102]. Thus, PTEN counteracts PI3K by preventing the
PIP3-mediated recruitment of the serine/threonine kinase
Akt to the cell membrane. As a consequence, Akt will not
be activated by a submembranous kinase and will not be
able to phosphorylate its many target proteins that stimu-
late cellular growth, proliferation and survival (Fig. 2).
Ample reports, from its discovery onwards [134], have
documented PTEN inactivation, either by mutation
(homozygous) deletion or through epigenetic mechanisms,
in high-grade gliomas [43]. Mice lacking PTEN expression
in astrocytes show an increased proliferation of these cells
[41]. In addition, PTEN loss contributes to the angiogenic
process featured in high-grade gliomas via upregulation of
VEGF transcript levels [113]. Several members of the JNK
family show increased levels in PTEN-deﬁcient glioma
cells as well, resulting in the simultaneous upregulation of
the JNK and PI3K pathway that feed into cellular processes
such as proliferation, survival, DNA repair and apoptosis
[151]. Intriguingly, in a recent study, the microRNA miR-
26a was disclosed as a direct regulator of PTEN expres-
sion: it appeared to be frequently ampliﬁed in human
glioma specimens with monoallelic PTEN loss, and miR-
26a-mediated PTEN repression-enhanced tumor formation
in a murine glioma model [58]. This epigenetic mechanism
for PTEN downregulation in glioma corroborates the Akt
signaling pathway as a major Achilles’ heel in the devel-
opment of these tumors (Fig. 2). For further details on
PTEN involvement in gliomagenesis, we refer to recent
dedicated reviews [22, 35, 76].
CDC25B and CDC25C
The human class III PTP subfamily comprises three
CDC25 variants that are all involved in cell cycle regula-
tion [120]. They positively regulate different stages of
mitosis, and are often found upregulated in human cancers,
where they cause aberrant cell cycle regulation and genetic
instability [13]. CDC25B (Fig. 3) has been linked to gli-
oma progression based on its high expression in WHO
grades III and IV astrocytomas when compared with the
levels in lower grade tumors, and may serve as a prognostic
marker in astrocytoma patients [104]. Also, CDC25C may
have bearing for glioma biology as revealed by experi-
ments involving the potential anticancer antibiotic
ansamycin. Ansamycin inhibits the activation of Hsp90 and
thus results in degradation of Hsp90 target proteins and
ultimately to cell cycle arrest and apoptosis [57, 71, 95].
Ansamycin treatment of glioma cell lines resulted in the
downregulation of CDC25C and Cdc2 levels, both proteins
that are involved in G2–M transition [44]. In lung cancer
cell lines, a similar effect was observed [126]. CDC25C
downregulation, therefore, could explain the ansamycin-
induced cell cycle arrest and apoptosis observed in glioma
cell lines. Future experiments will have to reveal whether a
similar effect on CDC25C can be exploited for glioma
treatment in vivo. All three CDC25 proteins have been
targets for pharmaceutical drug discovery, but no inhibitors
have so far been tested clinically.
PTP signaling signiﬁcance in glioma biology
The above illustrates that several PTPs are involved in
gliomagenesis, whereas the contribution of other PTPs is as
yet hypothetical (Table 1; Fig. 2). Especially, the results
obtained with permanent glioma cell lines should be
interpreted with care, since these model systems only
partially represent the molecular and pathological charac-
teristics of glial tumors.
A number of PTPs appear frequently mutated in glioma
tumor specimens, providing strong evidence for a causal
contribution to gliomagenesis. PTEN is inactivated by
mutation, deletion or gene silencing in a large portion of
these tumors, and several recent reviews are dedicated to its
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is located in a region that is often deleted in astrocytomas
(including GBMs) and oligodendrogliomas, suggestive of
an important role for PTPRD in glial cell functioning.
PTPRD-deﬁcient mice, however, while presenting neuro-
pathological symptoms [145], do not display increased glial
tumor susceptibility. Genomic alterations in glioma sam-
ples have also been detected for PTPRJ and PTPN11, but
since this concerns single cases it remains uncertain whe-
ther these mutations play a role in gliomagenesis or are
merely the consequence of genetic instability in these
tumors. The precedent of PTPN11 activating mutations in
leukemias speaks in favor of SHP-2 as an oncogenic protein
in sporadic gliomas. The status of PTPRJ as a cancer sus-
ceptibility gene [121] could as yet not be backed by
knockout studies; DEP-1-deﬁcient mice did not show an
increased tumor incidence, not even in colon [144].
Several PTPs have been linked to gliomagenesis based
on the stage-speciﬁc changes in their messenger and/or
protein expression levels. So far, it remains unclear by
which mechanism such PTP level changes are brought
about and whether the observed changes are functionally
relevant in an in vivo tumor setting. The changes in the
availability of crucial transcription factors or in the
accessibility of PTP gene regulatory sequences through
epigenetic mechanisms may play a role at the transcrip-
tional level, but also factors that impinge on mRNA and/or
protein stability may post-transcriptionally modulate PTP
levels and favor tumor growth. In line with this, small
compounds, such as etoposide, ansamycins and cadmium
induce the speciﬁc degradation of certain PTPs and result
in reduced proliferation and increased apoptosis in glioma
cell models. A clinically relevant hallmark of gliomas is
their very inﬁltrative growth pattern. Therefore, PTPs that
are known or suspected to be involved in adhesion and
migration of cells deserve special attention. Three of the
PTP genes that display altered expression levels in the
highly malignant GBM subtype have been linked to cel-
lular adhesion: PTPRD, PTPRM and DUSP26 (Table 1).
Also, PTPRZ, DUSP1, PTP4A3 and CDKN3, all impli-
cated in the control of cell migration, demonstrate aberrant
expression levels in GBM specimens (Table 1). It is
tempting to speculate that these alterations contribute to the
adhesive and migratory changes of glioma cells (Fig. 2).
Confounding issues in glioma research
So far, the acquired insight into the molecular mechanisms
underlying gliomagenesis has not yet resulted in markedly
improved treatment modalities for GBM patients. Several
reasons may account for this, including the often extensive
and diffuse inﬁltrative growth in the brain parenchyma, the
difﬁcult ‘druggability’ of this tumor type due to the blood–
brain barrier (BBB), and the lack of easily accessible and
clinically relevant glioma model systems for research
purposes. For instance, most glioma cell models do not
recapitulate the diffuse inﬁltrative growth pattern upon
introduction in the mouse brain [25, 37, 112]. Furthermore,
neither the ampliﬁcation of EGFR, which is found in
approximately 50% of the GBM patients, nor the expres-
sion of EGFRvIII is present in most GBM cell lines [10,
105, 109]. The use of short term, primary cultures does not
solve the problem because signiﬁcant genetic alterations
have been found after only a small number of passages in
glioma cultures [30, 81]. To create research models that
better recapitulate GBM features, including diffuse inﬁl-
trative growth, xenograft models have been developed
through orthotopic (the tissue from which the tumor orig-
inated) implantation of (primary) glioma cells into
immune-suppressed or immune-deﬁcient mice [5, 25, 40].
A drawback of these xenograft models is that grafts usually
lack accurate angiogenesis and that contributions by the
immune system cannot be considered [37]. The use of
genetically modiﬁed animal models that spontaneously
develop gliomas, therefore, seems a powerful approach [5,
59] and quite recently the generation of a mouse GBM
model in a region- and cell type-speciﬁc manner using
intracerebral lentiviral transduction was reported [92].
However, even in such powerful models,the BBB, which
regulates the composition of the central nervous system
interstitial ﬂuid by allowing low-molecular weight and lipid
compounds to pass while at the same time restricting access
of water-soluble compounds and macromolecules, may well
hamper the diffusion of chemotherapeutic agents to glioma
cells [98]. Consequently, progress in drug discovery for
glioblastoma treatment has been slow. DNA-alkylating
agents lomustine and carmustine were ﬁrst marketed over
30 years ago, while temozolomide is a more recent addition
in the same drug class [124, 137]. New insights into gli-
oma’s molecular drivers have led to the approval by the
FDA, in an accelerated review early 2009, of the use of
bevacizumab (avastin) against refractory GBM. In addition,
a number of clinical trials are ongoing or planned. Table 2
lists currently approved and experimental drugs for glio-
blastoma. Their mode of action is rather diverse and given
the number of compounds that target PTKs or their down-
stream effectors one may expect PTP targeting drugs to
enter the pipeline in the near future.
The potential therapeutic and diagnostic use of PTP
signaling pathways in gliomas
Glioma patients are still facing a very poor prognosis and,
in view of the limited durability of surgical and local
168 Acta Neuropathol (2010) 119:157–175
123irradiation treatments and small number of applicable
drugs (Table 2), research efforts aim at the identiﬁcation of
novel targets. PTPs that are linked to glioma development
and progression thus represent potential starting points in
glioma diagnostic and therapeutic strategies. A prime
candidate is of course the PTEN tumor suppressor that is so
frequently inactivated in GBM. To overcome this loss of
function, the PI3K pathway needs to be suppressed and
several inhibitors of PI3K signaling are being evaluated for
clinical use. Rapamycin is a widely used drug that inhibits
mTOR, a downstream target of AKT [12]. Unfortunately, a
recent phase I clinical trial revealed that rapamycin treat-
ment leads to increased AKT phosphorylation in PTEN-
deﬁcient GBM patients, probably due to the relief from a
negative feedback loop created by mTOR [26]. This indi-
cates that PI3K signaling should be targeted more upstream
to become useful in anti-glioma strategies.
Apoptosis resistance of gliomas provides yet another
hurdle on the road towards effective therapies against these
tumors. Several PTPs have been associated with apoptosis
signaling pathways in gliomas (Fig. 2), which potentially
makes them therapeutic targets. For instance, the ﬁnding
that in glioma cell lines the anti-diabetic and anti-inﬂam-
matory drug troglitazone activates PTP1B and, as a
consequence, downregulates the anti-apoptotic FLIP and
Bcl2 proteins [4] urges for a follow-up in in vivo glioma
models. Likewise, compounds that speciﬁcally inhibit
PTPN13, the negative regulator of FAS-mediated apoptosis
in glioma cell lines [39], may enhance the sensitivity of
glial tumor cells to undergo apoptosis, e.g. following radio-
or chemotherapy.
Targeting of gliomas via the blood stream implies suc-
cessful transfer over the BBB, an obstacle that prevents
adequate effect of many agents in diseases of the central
nervous system. In the design of small compound inhibitors
for glioma-relevant PTPs, one therefore has to take the BBB
into account. Likewise, the exploitation of (monoclonal)
antibodies, nowadays common agents to ﬁght cancer
growth, to speciﬁcally target glioma cells in the brain is
limited by the BBB [123]. To circumvent this problem,
antibodies that for example inhibit EGFR and VEGFR
signaling might be injected directly intracerebrally.
Table 2 Approved and experimental drugs for glioblastoma
Drug name Mode of action Status Notes
Lomustine Alkylating agent Marketed
Carmustine Alkylating agent Marketed Also sold as slow-release polymeric wafer
system under Gliadel

Temozolomide Alkylating agent Marketed Prodrug, indicated for newly diagnosed
glioblastoma multiforme
Bevacizumab (Avastin) Anti-VEGF Approved in 2009
Nimotuzumab Anti-EGFR Phase 3
TM601 Tumor cell binder, antiangiogenic Phase 3 planned Synthetic form of the scorpion venom
peptide chlorotoxin; also as
radiolabelled formulations
MPC-6827 (Azixa) Microtubule-destabilizing agent Phase 2
CDX-110 EGFRvIII vaccine Phase 2
Cotara 131I-radiolabelled mAb conjugate Phase 2
XL184 RTK inhibitor Phase 2 Targets Met, VEGFR2, Kit, Flt-3 and Tie-
2
TLN-4601 Peripheral benzodiazepine receptor (PBR) ligand Phase 2 Inhibitor of the RAS-mitogen-activated
protein kinase (MAPK) pathway
CYT997 Vascular targeting agent and tubulin inhibitor Phase 2
BSI-201 PARP-1 inhibitor Phase 2
Banoxantrone (AQ4 N) Topoisomerase inhibitor and DNA intercalator Phase 2 Prodrug, activated by hypoxia
ICT-121 CD133 peptide vaccine Phase 1 Trial planned 2010
ICT-107 Dendritic cell-based vaccine Phase 1 Uses patient-derived, speciﬁcally primed
dendritic cells
MP-470 Multiple TRKi and Rad51 DNA repair inhibitor Phase 1
BioWorld
 Today (AHC Media LLC), Thomson Pharma
 IDdb, Pharmaprojects, Company and NIH websites
Experimental treatments are usually tested in combination with approved therapies
This table shows that more recently developed compounds are targeting speciﬁc signaling pathways rather than the general DNA damaging effect
of the earlier drugs
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bodies in glioma therapies was obtained using a monoclonal
antibody against the extracellular domain of the short
RPTPf transmembrane isoform [38]. When coupled to the
cytostatin saporin, the antibody killed U87MG glioma cells
in vitro and it signiﬁcantly delayed in vivo tumor growth of
a U87MG xenograft. As mentioned before, such cell-based
models do not recapitulate all pathobiological features of
gliomas and the therapeutic potential of this approach needs
further investigation. Irrespective, these results urge for
further studies on the use of monoclonal antibodies against
receptor-type PTPs as tumor-directed agents in glioma
therapies. In addition, in view of the often altered expres-
sion levels for several of the PTPs discussed here in GBM
specimens when compared with normal glial tissue, the
assessment of PTP expression levels in tumor tissue may
well serve to reﬁne GBM staging, aid in the design of
combinatorial treatment protocols and/or support the mon-
itoring of treatment responses.
Concluding remarks
Ample evidence indicates an important role for PTPs in
development and progression of tumors, including gliomas.
Alterations in multiple PTP genes and their products have
been noted in gliomas. However, careful assessment of their
exact functional relevance in glioma biology is needed.
Functional studies on PTP signaling in other tumor systems
will of course be of value but, in view of the unique growth
and dispersion characteristics of gliomas, studies using
tumor models that faithfully mimic glioma biology are
mandatory. This will ultimately allow a better validation of
glioma treatment modalities and enable improvement in the
poor prognosis glioma patients still face today.
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